STOCK TITAN

[Form 4] Annovis Bio, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Michael B. Hoffman, a director of Annovis Bio, Inc. (ANVS), reported purchases of company common stock on 08/29/2025. He acquired three blocks of 5,000 shares each at prices of $2.28, $2.29, and $2.30, increasing his direct holdings from 1,469,929 to 1,479,929 shares. The filing also discloses indirect beneficial ownership of 223,357 shares held in the 2018 Jane and Michael Hoffman Descendants Trust, over which he has voting and investment power. The Form 4 is signed by an attorney-in-fact on behalf of the reporting person.

Michael B. Hoffman, membro del consiglio di Annovis Bio, Inc. (ANVS), ha segnalato acquisti di azioni ordinarie della società in data 08/29/2025. Ha acquistato tre blocchi da 5.000 azioni ciascuno ai prezzi di $2.28, $2.29 e $2.30, portando la sua detenzione diretta da 1.469.929 a 1.479.929 azioni. La comunicazione indica inoltre una partecipazione indiretta di 223.357 azioni detenuta nel 2018 Jane and Michael Hoffman Descendants Trust, sulla quale esercita poteri di voto e di investimento. Il modulo Form 4 è firmato da un procuratore in rappresentanza del soggetto segnalante.

Michael B. Hoffman, director de Annovis Bio, Inc. (ANVS), informó la compra de acciones ordinarias de la compañía el 08/29/2025. Adquirió tres bloques de 5.000 acciones cada uno a precios de $2.28, $2.29 y $2.30, incrementando su participación directa de 1.469.929 a 1.479.929 acciones. La presentación también revela una tenencia indirecta de 223.357 acciones en el 2018 Jane and Michael Hoffman Descendants Trust, sobre la cual tiene poder de voto e inversión. El Formulario 4 está firmado por un apoderado en nombre de la persona informante.

Annovis Bio, Inc. (ANVS)의 이사인 Michael B. Hoffman이 2025년 08월 29일 회사 보통주를 매수했다고 보고했습니다. 그는 각각 $2.28, $2.29, 및 $2.30의 가격으로 5,000주씩 세 블록을 취득하여 직접 보유 주식을 1,469,929주에서 1,479,929주로 늘렸습니다. 제출서류는 또한 그가 의결권 및 투자권을 보유한 2018 Jane and Michael Hoffman Descendants Trust에 보관된 간접적 수익권 223,357주를 공개합니다. Form 4는 보고인을 대신하여 위임인이 서명했습니다.

Michael B. Hoffman, administrateur d'Annovis Bio, Inc. (ANVS), a déclaré des achats d'actions ordinaires de la société le 29/08/2025 (08/29/2025). Il a acquis trois tranches de 5 000 actions chacune aux prix de $2.28, $2.29 et $2.30, portant ses détentions directes de 1 469 929 à 1 479 929 actions. Le dépôt révèle également une participation bénéficiaire indirecte de 223 357 actions détenue dans le 2018 Jane and Michael Hoffman Descendants Trust, sur laquelle il exerce les pouvoirs de vote et d'investissement. Le formulaire Form 4 est signé par un mandataire au nom de la personne déclarante.

Michael B. Hoffman, Direktor von Annovis Bio, Inc. (ANVS), meldete Aktienkäufe des Unternehmens am 29.08.2025 (08/29/2025). Er erwarb drei Pakete zu je 5.000 Aktien zu Preisen von $2.28, $2.29 und $2.30 und erhöhte damit seine direkte Beteiligung von 1.469.929 auf 1.479.929 Aktien. Die Einreichung weist zudem auf eine indirekte wirtschaftliche Beteiligung von 223.357 Aktien im 2018 Jane and Michael Hoffman Descendants Trust hin, über die er Stimm- und Anlagebefugnisse ausübt. Das Formular Form 4 ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

Positive
  • Insider purchases of 15,000 shares on 08/29/2025 at prices between $2.28 and $2.30
  • Increased direct ownership reported to 1,479,929 shares after the transactions
  • Transparency on indirect holdings: 223,357 shares held in the 2018 Jane and Michael Hoffman Descendants Trust with voting and investment power disclosed
Negative
  • None.

Insights

TL;DR: Insider purchases totaling 15,000 shares on 08/29/2025, modestly increasing direct stake.

The reported transactions show three small-market purchases totaling 15,000 common shares at prices between $2.28 and $2.30. Post-transactions direct ownership is reported as 1,479,929 shares, plus 223,357 shares held indirectly through a family trust. These are explicit, contemporaneous purchases by a director rather than option exercises or dispositions. From a financial-analysis perspective, the filing documents additional insider accumulation but does not include company financials, material corporate actions, or indications of size relative to outstanding shares, so its standalone market impact is likely limited.

TL;DR: Director reported routine open-market buys and disclosed trust-held indirect ownership and control.

The Form 4 complies with Section 16 reporting by showing the director's acquisitions and clarifies the nature of indirect ownership via the 2018 family trust, stating the reporting person has voting and investment power. Transactions are clearly dated and priced, and the filing is signed by an attorney-in-fact. There are no disclosures of departures, new arrangements, or other governance actions. This is a standard insider transaction disclosure without governance red flags in the form itself.

Michael B. Hoffman, membro del consiglio di Annovis Bio, Inc. (ANVS), ha segnalato acquisti di azioni ordinarie della società in data 08/29/2025. Ha acquistato tre blocchi da 5.000 azioni ciascuno ai prezzi di $2.28, $2.29 e $2.30, portando la sua detenzione diretta da 1.469.929 a 1.479.929 azioni. La comunicazione indica inoltre una partecipazione indiretta di 223.357 azioni detenuta nel 2018 Jane and Michael Hoffman Descendants Trust, sulla quale esercita poteri di voto e di investimento. Il modulo Form 4 è firmato da un procuratore in rappresentanza del soggetto segnalante.

Michael B. Hoffman, director de Annovis Bio, Inc. (ANVS), informó la compra de acciones ordinarias de la compañía el 08/29/2025. Adquirió tres bloques de 5.000 acciones cada uno a precios de $2.28, $2.29 y $2.30, incrementando su participación directa de 1.469.929 a 1.479.929 acciones. La presentación también revela una tenencia indirecta de 223.357 acciones en el 2018 Jane and Michael Hoffman Descendants Trust, sobre la cual tiene poder de voto e inversión. El Formulario 4 está firmado por un apoderado en nombre de la persona informante.

Annovis Bio, Inc. (ANVS)의 이사인 Michael B. Hoffman이 2025년 08월 29일 회사 보통주를 매수했다고 보고했습니다. 그는 각각 $2.28, $2.29, 및 $2.30의 가격으로 5,000주씩 세 블록을 취득하여 직접 보유 주식을 1,469,929주에서 1,479,929주로 늘렸습니다. 제출서류는 또한 그가 의결권 및 투자권을 보유한 2018 Jane and Michael Hoffman Descendants Trust에 보관된 간접적 수익권 223,357주를 공개합니다. Form 4는 보고인을 대신하여 위임인이 서명했습니다.

Michael B. Hoffman, administrateur d'Annovis Bio, Inc. (ANVS), a déclaré des achats d'actions ordinaires de la société le 29/08/2025 (08/29/2025). Il a acquis trois tranches de 5 000 actions chacune aux prix de $2.28, $2.29 et $2.30, portant ses détentions directes de 1 469 929 à 1 479 929 actions. Le dépôt révèle également une participation bénéficiaire indirecte de 223 357 actions détenue dans le 2018 Jane and Michael Hoffman Descendants Trust, sur laquelle il exerce les pouvoirs de vote et d'investissement. Le formulaire Form 4 est signé par un mandataire au nom de la personne déclarante.

Michael B. Hoffman, Direktor von Annovis Bio, Inc. (ANVS), meldete Aktienkäufe des Unternehmens am 29.08.2025 (08/29/2025). Er erwarb drei Pakete zu je 5.000 Aktien zu Preisen von $2.28, $2.29 und $2.30 und erhöhte damit seine direkte Beteiligung von 1.469.929 auf 1.479.929 Aktien. Die Einreichung weist zudem auf eine indirekte wirtschaftliche Beteiligung von 223.357 Aktien im 2018 Jane and Michael Hoffman Descendants Trust hin, über die er Stimm- und Anlagebefugnisse ausübt. Das Formular Form 4 ist von einem Bevollmächtigten im Namen der meldenden Person unterschrieben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hoffman Michael B

(Last) (First) (Middle)
C/O ANNOVIS BIO, INC.
101 LINDENWOOD DR, SUITE 225

(Street)
MALVERN PA 19355

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Annovis Bio, Inc. [ ANVS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/29/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/29/2025 A 5,000 A $2.28 1,469,929 D
Common Stock 08/29/2025 A 5,000 A $2.29 1,474,929 D
Common Stock 08/29/2025 A 5,000 A $2.3 1,479,929 D
Common Stock 223,357 I The 2018 Jane and Michael Hoffman Descendants Trust(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares are held in a family trust formed by the reporting person and the reporting person has voting and investment power over such shares.
/s/ Maria Maccecchini Attorney-in-Fact 09/03/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Michael B. Hoffman report on Form 4 for ANVS?

He reported three open-market acquisitions on 08/29/2025 totaling 15,000 common shares at prices of $2.28, $2.29, and $2.30.

How many ANVS shares does Hoffman beneficially own after these transactions?

The filing reports 1,479,929 shares held directly following the reported transactions, plus 223,357 shares held indirectly via a family trust.

What is the nature of Hoffman's indirect ownership disclosed in the Form 4?

The indirect holdings are in the 2018 Jane and Michael Hoffman Descendants Trust, and the reporting person has voting and investment power over those shares.

Was this Form 4 signed by the reporting person?

The filing shows a signature block executed by Maria Maccecchini, Attorney-in-Fact dated 09/03/2025 on behalf of the reporting person.

Are there any dispositions or derivative transactions reported in this filing?

No dispositions or derivative security transactions are reported; the filing lists only the non-derivative acquisitions and the indirect trust holding.
Annovis Bio Inc

NYSE:ANVS

ANVS Rankings

ANVS Latest News

ANVS Latest SEC Filings

ANVS Stock Data

45.01M
16.61M
14.78%
14.59%
11.23%
Biotechnology
Pharmaceutical Preparations
Link
United States
MALVERN